In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Evolus Inc (NASDAQ: EOLS), with a price target of $35. The company’s shares opened today at $13.47.
Chen wrote:
“We reaffirm our Overweight rating on EOLS. Based on our due diligence, we learned that dermatologists and plastic surgeons appreciate the value proposition of Evolus’s botulinum toxin as a nearly identical product to market-leader Botox sold at a discount. Therefore, we think DWP-450 could pick up meaningful market share if it is approved. and other potential upcoming catalysts should drive EOLS shares higher.”
According to TipRanks.com, Chen is a 5-star analyst with an average return of 11.6% and a 40.7% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Aridis Pharmaceuticals Inc, and Melinta Therapeutics Inc.
Currently, the analyst consensus on Evolus Inc is a Strong Buy with an average price target of $29.67, which is a 120.3% upside from current levels. In a report issued on October 10, Mizuho Securities also reiterated a Buy rating on the stock with a $27 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.50 and a one-year low of $6.75. Currently, Evolus Inc has an average volume of 390.7K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evolus, Inc. is a medical aesthetics company. The company is engaged in providing physicians and patients with expanded choices in aesthetic procedures and treatments. Evolus was founded in November, 2012 and is headquartered in Irvine, CA.
